AUY922
- Generic Name
- AUY922
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H33N3O5
- CAS Number
- 747412-64-2
- Unique Ingredient Identifier
- G1G66XE93W
- Background
AUY922 has been used in trials studying the treatment of Lymphoma, Breast Cancer, Metastatic Disease, Advanced Solid Tumors, and Hematologic Neoplasms, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT01402401
- Locations
- 🇺🇸
University of California at Los Angeles UCLA LeConte Location, Los Angeles, California, United States
🇺🇸University of Texas/MD Anderson Cancer Center UT SC, Houston, Texas, United States
🇪🇸Novartis Investigative Site, Barcelona, Cataluña, Spain
A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- National Health Research Institutes, Taiwan
- Target Recruit Count
- 25
- Registration Number
- NCT01389583
- Locations
- 🇨🇳
National Health Research of Institutes, Taiwan Cooperative Oncology Group, Tainan, Taiwan
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer
- Conditions
- Interventions
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Swedish Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01294826
- Locations
- 🇺🇸
Swedish Medical Center Cancer Institute, Seattle, Washington, United States
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT01271920
- Locations
- 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
🇺🇸Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States
Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT01132625
- Locations
- 🇯🇵
Novartis Investigative Site, Sunto-gun, Shizuoka, Japan
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 153
- Registration Number
- NCT01124864
- Locations
- 🇺🇸
University of California at Los Angeles UCLA - Santa Monica, Los Angeles, California, United States
🇺🇸St. Luke's Hospital and Health Network St Luke's, Bethlehem, Pennsylvania, United States
🇺🇸Dana Farber Cancer Institute DFCI, Boston, Massachusetts, United States
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 68
- Registration Number
- NCT01084330
- Locations
- 🇺🇸
University of California at Los Angeles Dept. of UCLA (4), Los Angeles, California, United States
🇺🇸Horizon Oncology Center, Lafayette, Indiana, United States
🇺🇸Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology, Dallas, Texas, United States
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
- Conditions
- Interventions
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 29
- Registration Number
- NCT00708292
- Locations
- 🇺🇸
Mayo Clinic - Arizona Cancer Clinical Research Unit, Scottsdale, Arizona, United States
🇺🇸Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3), San Antonio, Texas, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.